All In Biotech

Drug Trial Radar · NCT04620135

Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

A Single-masked, Randomized, Multi-center, Parallel-group, 4-week Study Evaluating the Efficacy and Safety of Once Daily Netarsudil Ophthalmic Solution 0.02% Compared to Twice Daily Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% in Japanese Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Last checked: Nov 19, 2026Latest source record: Feb 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 245 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

245

Actual

Start

Nov 30, 2020

Primary completion

Jul 9, 2021

Study completion Jul 30, 2021

Sponsor

Lead sponsor
Aerie PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Nov 6, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 3 Study Comparing the Efficacy and Safety of Netarsudil Ophthalmic Solution 0.02% QD to Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% BID, for Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension Over A 4-Week Period.

Conditions

  • Primary Open Angle Glaucoma
  • Ocular Hypertension

Interventions

  • Netarsudil ophthalmic solution 0.02%Drug

    Topical sterile ophthalmic solution Other Name: Rhopressa®

  • Ripasudil hydrochloride hydrate ophthalmic solution 0.4%Drug

    Other Name: Glanatec®

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Intraocular Pressure (IOP)Time frame: 29 Days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Seijo Clinic

    Setagaya-Ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.